Healius Limited (ASX: HLS)

Market Cap	991.17M
Revenue (ttm)	1.75B
Net Income (ttm)	-645.80M
Shares Out	726.13M
EPS (ttm)	-0.98
PE Ratio	n/a
Forward PE	247.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,165,857
Open	1.380
Previous Close	1.400
Day's Range	1.355 - 1.400
52-Week Range	1.080 - 1.860
Beta	0.73
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 26, 2024

About Healius

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics, QML Pathology, TML Pathology, Abbott Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 9,658
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: HLS

Financial Performance

In 2024, Healius's revenue was 1.75 billion, an increase of 2.30% compared to the previous year's 1.71 billion. Losses were -645.80 million, 75.6% more than in 2023.